Shen J, Li J, Lei Y, Chen Z, Wu L, Lin C
Heliyon. 2024; 10(10):e30955.
PMID: 38774317
PMC: 11107250.
DOI: 10.1016/j.heliyon.2024.e30955.
Subramaniam S, Kothari H, Bosmann M
Thromb Res. 2022; 220:35-47.
PMID: 36265412
PMC: 9525243.
DOI: 10.1016/j.thromres.2022.09.025.
Andaluz-Ojeda D, Vidal-Cortes P, Aparisi Sanz A, Suberviola B, Del Rio Carbajo L, Nogales Martin L
World J Crit Care Med. 2022; 11(4):269-297.
PMID: 36051937
PMC: 9305685.
DOI: 10.5492/wjccm.v11.i4.269.
Chen C, Yang Y, Tsai H, Tung T
Front Med (Lausanne). 2022; 9:838904.
PMID: 35433719
PMC: 9005748.
DOI: 10.3389/fmed.2022.838904.
Hu H, Pan H, Li R, He K, Zhang H, Liu L
Front Pharmacol. 2022; 13:802228.
PMID: 35237162
PMC: 8883392.
DOI: 10.3389/fphar.2022.802228.
Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
Peng J, She X, Mei H, Zheng H, Fu M, Liang G
Aging (Albany NY). 2022; 14(2):557-571.
PMID: 35038318
PMC: 8833131.
DOI: 10.18632/aging.203834.
Targeting the NLRP3 inflammasome in cardiovascular diseases.
Toldo S, Mezzaroma E, Buckley L, Potere N, Di Nisio M, Biondi-Zoccai G
Pharmacol Ther. 2021; 236:108053.
PMID: 34906598
PMC: 9187780.
DOI: 10.1016/j.pharmthera.2021.108053.
Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
Rubio-Rivas M, Forero C, Mora-Lujan J, Montero A, Formiga F, Homs N
Pharmacotherapy. 2021; 41(11):884-906.
PMID: 34558742
PMC: 8661749.
DOI: 10.1002/phar.2627.
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
Singh A, Oks M, Husk G, Dechario S, Mina B, Singh K
Respir Care. 2021; 66(12):1805-1814.
PMID: 34548407
PMC: 9993783.
DOI: 10.4187/respcare.08779.
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
Russo G, Solimini A, Zuccala P, Zingaropoli M, Carraro A, Pasculli P
PLoS One. 2021; 16(9):e0257376.
PMID: 34506608
PMC: 8432821.
DOI: 10.1371/journal.pone.0257376.
Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.
Mahroum N, Watad A, Bridgewood C, Mansour M, Nasr A, Hussein A
Int J Environ Res Public Health. 2021; 18(17).
PMID: 34501738
PMC: 8431489.
DOI: 10.3390/ijerph18179149.
Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review.
Starshinova A, Malkova A, Zinchenko U, Kudlay D, Glushkova A, Dovgalyk I
Life (Basel). 2021; 11(8).
PMID: 34440497
PMC: 8400016.
DOI: 10.3390/life11080753.
Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
Dravid A, Kashiva R, Khan Z, Memon D, Kodre A, Potdar P
Medicine (Baltimore). 2021; 100(29):e26705.
PMID: 34398044
PMC: 8294888.
DOI: 10.1097/MD.0000000000026705.
Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis.
Conti V, Corbi G, Sellitto C, Sabbatino F, Maci C, Bertini N
J Pers Med. 2021; 11(7).
PMID: 34357095
PMC: 8307114.
DOI: 10.3390/jpm11070628.
Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis.
Jiang W, Li W, Wu Q, Han Y, Zhang J, Luo T
Infect Dis Ther. 2021; 10(3):1677-1698.
PMID: 34244956
PMC: 8269405.
DOI: 10.1007/s40121-021-00483-x.
Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date.
Kenny G, Mallon P
Expert Rev Clin Pharmacol. 2021; 14(10):1279-1287.
PMID: 34187281
PMC: 8330014.
DOI: 10.1080/17512433.2021.1949286.
Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study.
Hu Q, Xu Y, Xiang Y, Wang B, Yuan Z, Shan Y
Int J Biol Sci. 2021; 17(8):2124-2134.
PMID: 34131411
PMC: 8193270.
DOI: 10.7150/ijbs.56952.
Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).
Chen C, Hu F, Wei J, Yuan L, Wen T, Gale R
Leukemia. 2021; 35(6):1661-1670.
PMID: 34002026
PMC: 8127467.
DOI: 10.1038/s41375-021-01264-8.
Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
Wei Q, Lin H, Wei R, Chen N, He F, Zou D
Infect Dis Poverty. 2021; 10(1):71.
PMID: 34001244
PMC: 8128625.
DOI: 10.1186/s40249-021-00857-w.
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C, Calabrese C, Garofalo E, Bruni A, Vatrella A, Pelaia G
Int J Mol Sci. 2021; 22(6).
PMID: 33802761
PMC: 8002419.
DOI: 10.3390/ijms22063059.
